HOME >> MEDICINE >> NEWS
Chronic sinusitis sufferers have enhanced immune responses to fungi

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have discovered that people with chronic sinus inflammation have an exaggerated immune response to common airborne fungi. The results of their study appear online today in The Journal of Allergy and Clinical Immunology.

"This study is the first to show a possible immunologic basis for chronic sinusitis, an important starting point to better understand the etiology of the illness," says Marshall Plaut, M.D., chief of NIAID's allergic mechanisms section. Despite the enormous health impact of chronic sinusitis--nearly 30 million people were diagnosed with sinusitis in 2002, according to U.S. Centers for Disease Control and Prevention, and direct costs of the illness exceed $5.6 billion per year--the condition is very poorly understood, he says.

The researchers, led by Hirohito Kita, M.D., of the Mayo Clinic in Rochester, MN, compared blood samples taken from 18 people diagnosed with chronic sinusitis with blood samples from 15 healthy volunteers. Nasal secretions from the two groups were also examined for the presence of fungal proteins and inflammation-causing immune system molecules.

Airborne microscopic fungi spores abound indoors and out. People may inhale a million or more fungal spores each day, notes Dr. Kita. The mere presence of such fungi in the airways, however, is not enough to cause sinusitis because these spores can be found in the upper respiratory tracts of both sinusitis sufferers and non-sufferers. Indeed, in this study, levels of fungal proteins in nasal secretions were similar in both groups.

The Mayo Clinic scientists looked for evidence that people with sinusitis respond abnormally to these harmless fungi. The investigators exposed immune cells derived from the blood samples to extracts of four common airborne fungi: Alternaria, Aspergillus, Penicillium and Cladosporium. T
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
8-Oct-2004


Page: 1 2

Related medicine news :

1. Chronic pain treatments more effective when taken together, new study shows
2. Chronic fatigue patients show lower response to placebos
3. Chronic back pain shrinks thinking parts of the brain, study finds
4. Chronic diseases need global health attention
5. Chronic care medicine: Physicians say help!
6. Chronic fatigue syndrome and Gulf War veterans
7. Chronic stress researcher to speak at NCCAMs Distinguished Lecture Series
8. Chronic cough significantly impacts life quality in women
9. Chronic diseases linked to falls in elderly women
10. Chronic fatigue syndrome is rare in children
11. Chronic drinking increases cortisol during intoxication and withdrawal

Post Your Comments:
(Date:5/24/2013)... News) -- Drugs commonly used to treat glaucoma may ... interfere with vision, according to a new study. ... used to reduce eye pressure, have already been shown ... color, the researchers said, suggesting that the new findings ... Doctors should be conservative when prescribing these drugs, the ...
(Date:5/24/2013)... Let’s face it: very few are luckily ... the majority of people to be uncomfortable with the color ... coffee addiction or simply genetics, yellowish or stained teeth suppresses ... , Herald Square Dental is proud to announce ... Venus White Max. , Teeth become discolored for a ...
(Date:5/24/2013)... Chino, CA (PRWEB) May 24, 2013 Area ... huge selection of new hot tubs to choose from at ... Super Sale . The sales event takes place at ... May 26, 2013. , Jacuzzi, the industry's leading hot ... sale traveling across the country. The event will feature popular ...
(Date:5/24/2013)... New York (PRWEB) May 24, 2013 ... lawsuit involving Intuitive Surgical Inc.’s da Vinci Surgical ... to court records, a Washington State Court jury ruled ... negligence in training a surgeon who performed a da ... later. The patient’s family had alleged in their ...
(Date:5/24/2013)... development of infantile myofibromatosis (IM)a disorder characterized by multiple ... new therapeutic targets, according to researchers from the Icahn ... in the American Journal of Human Genetics , ... disease, for which the only current treatment option is ... an inheritied disorder that develops in infancy or even ...
Breaking Medicine News(10 mins):Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2
(Date:5/23/2013)... SAN DIEGO y PARÍS, 24 de ... VOLC ), un destacado desarrollador y fabricante ... para mejorar la diagnosis y tratamiento de la ... resultados preliminares del ensayo ADVISE ( Ad enosine ... tenosis E valuation) II durante la sesión ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. ... stage medical device company that develops and sells high ... of its rights offering.  In addition, the concurrent temporary ... warrants expired on May 17, 2013. Nephros ... million from the rights offering.   A portion of the ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
Cached News: